Physician profile
Jeffrey Haberman
NPI 1538130802
$4,314.21
in general payments reported to CMS, 2019-2025
28 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $262 · 2021: $518 · 2022: $747 · 2023: $974 · 2024: $890 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,559.04 |
| Education | $120.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $804.18 | 2020-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $483.80 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $425.39 | 2021-2025 | Urolift |
| Dendreon Pharmaceuticals LLC | $349.75 | 2021-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $292.26 | 2022-2025 | |
| Pfizer INC. | $269.39 | 2020-2025 | |
| Procept Biorobotics Corporation | $243.87 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $219.65 | 2020-2024 | Xtandi, Myrbetriq |
| Neotract INC. | $199.40 | 2019-2020 | |
| Myovant Sciences INC. | $175.44 | 2021-2022 | |
| Srs Medical Systems, INC. | $148.63 | 2024 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Urovant Sciences INC | $90.56 | 2021-2022 | |
| Endo USA, INC. | $81.86 | 2025 | Aveed, Xiaflex |
| Tolmar Pharmaceuticals, INC. | $62.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.44 | 2022-2023 | Keytruda, Welireg, Lynparza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $60.00 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $46.57 | 2021 | |
| Tolmar, INC. | $41.59 | 2024-2025 | Eligard |
| Amgen INC. | $37.97 | 2022-2023 | Xgeva |
| Accord Healthcare, INC. | $36.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $26.29 | 2023 | Pylarify |
| Blue Earth Diagnostics | $24.68 | 2022 | |
| Myriad Genetic Laboratories, INC. | $23.94 | 2023 | Prolaris |
| Abbvie INC. | $21.98 | 2022 | |
| Rochester Medical Corporation | $20.45 | 2020 | |
| Telix Pharmaceuticals | $17.04 | 2022 | |
| Olympus America INC. | $13.41 | 2023 | Visera 4k Uhd Camera Control Unit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Haberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.